Cargando…

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site

The BCR/ABL1 inhibitor Nilotinib is increasingly used to treat patients with chronic myeloid leukemia (CML). Although otherwise well-tolerated, Nilotinib has been associated with the occurrence of progressive arterial occlusive disease (AOD). Our objective was to determine the exact frequency of AOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hadzijusufovic, Emir, Albrecht-Schgoer, Karin, Huber, Kilian, Hoermann, Gregor, Grebien, Florian, Eisenwort, Gregor, Schgoer, Wilfried, Herndlhofer, Susanne, Kaun, Christoph, Theurl, Markus, Sperr, Wolfgang R., Rix, Uwe, Sadovnik, Irina, Jilma, Bernd, Schernthaner, Gerit H., Wojta, Johann, Wolf, Dominik, Superti-Furga, Giulio, Kirchmair, Rudolf, Valent, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669463/ https://www.ncbi.nlm.nih.gov/pubmed/28757617 http://dx.doi.org/10.1038/leu.2017.245

Ejemplares similares

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Secretoneurin Gene Therapy Improves Blood Flow in an Ischemia Model in Type 1 Diabetic Mice by Enhancing Therapeutic Neovascularization
por: Schgoer, Wilfried, et al.
Publicado: (2013)

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population
por: Graf, Irene, et al.
Publicado: (2022)

Engraftment in NSG(SCF) mice correlates with the WHO category and prognosis in systemic mastocytosis
por: Willmann, Michael, et al.
Publicado: (2023)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph(+) Chronic Myeloid Leukemia
por: Sadovnik, Irina, et al.
Publicado: (2022)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Cell‐based and antibody‐mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues
por: Valent, Peter, et al.
Publicado: (2020)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2019)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
por: Peter, Barbara, et al.
Publicado: (2017)

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
por: Valent, Peter, et al.
Publicado: (2018)

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph(+) chronic myeloid leukemia
por: Peter, Barbara, et al.
Publicado: (2022)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

The novel angiogenic cytokine secretoneurin promotes angiogenesis, arteriogenesis and vasculogenesis in the mouse hind-limb ischemia model
por: Schgoer, Wilfried, et al.
Publicado: (2008)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

Targeting allosteric regulatory modules in oncoproteins: “Drugging the Undruggable”
por: Hantschel, Oliver, et al.
Publicado: (2011)

Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
por: Heinemann, Tim, et al.
Publicado: (2022)

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
por: Stefanzl, Gabriele, et al.
Publicado: (2017)

Cerebral Malaria: Current Clinical and Immunological Aspects
por: Albrecht-Schgoer, Karin, et al.
Publicado: (2022)

Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms
por: Willmann, Michael, et al.
Publicado: (2018)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
por: Graf, Irene, et al.
Publicado: (2023)

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
por: Hoermann, Gregor, et al.
Publicado: (2015)

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2021)

In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells
por: Gamperl, Susanne, et al.
Publicado: (2020)

The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils
por: Blatt, Katharina, et al.
Publicado: (2012)

Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology
por: Hoermann, Gregor, et al.
Publicado: (2020)

Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal
por: Willmann, Michael, et al.
Publicado: (2021)

Regulation of Lymphatic GM-CSF Expression by the E3 Ubiquitin Ligase Cbl-b
por: Peer, Sebastian, et al.
Publicado: (2018)

A Computational Approach to Analyze the Mechanism of Action of the Kinase Inhibitor Bafetinib
por: Burkard, Thomas R., et al.
Publicado: (2010)

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects
por: Culen, Martin, et al.
Publicado: (2016)

A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL
por: Rix, Uwe, et al.
Publicado: (2013)

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal()
por: Valent, Peter, et al.
Publicado: (2017)

Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
por: Valent, Peter, et al.
Publicado: (2021)

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
por: Schernthaner, Guntram, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9js39hg4j5cg9sk9s2gcv75vv8